DEA Labels Lab Buzz as Cannabimimetic Schedule I Threats
Published Date: 1/20/2026
Rule
Summary
Starting February 19, 2026, the DEA is officially defining “cannabimimetic agents” and adding 18 new substances to this group, all still Schedule I drugs. They’re also simplifying things by giving most of these substances one single drug code, making tracking easier. This update affects manufacturers, law enforcement, and anyone handling these substances, but it won’t change their legal status or cause new fees.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Eighteen substances formally listed
Starting February 19, 2026, DEA adds 18 additional named substances to the definition of “cannabimimetic agents.” All 18 substances remain Schedule I controlled substances, so their legal schedule status does not change.
Single DEA drug code for most agents
DEA consolidates most existing administration controlled substances codes for cannabimimetic agents into a single drug code number 7000 when the rule takes effect on February 19, 2026, to simplify tracking and reporting.
Two substances moved but keep existing codes
JWH-018 and AM2201 are moved to 21 CFR 1308.11(d) but retain their existing drug codes (7118 and 7201) to facilitate quota and international reporting; upon that move, positional isomers of these two substances will be defined as Schedule I controlled substances.
No new fees or reporting obligations
DEA states this final rule does not change the Schedule I status of listed substances, does not impose new regulatory controls, recordkeeping, reporting requirements, or information-collection burdens, and will not create new fees for handlers.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-00904 — Commercial Non-Power Production or Utilization Facilities
The Nuclear Regulatory Commission just clarified that commercial non-power nuclear facilities must follow certain safety update rules, while non-commercial ones don’t. This change kicks in right away and affects businesses running these facilities, who now have 30 days to share their thoughts. No new fees are mentioned, but staying in the loop is key to avoid surprises!
Next: 2026-00909 — Allocation of Assets in Single-Employer Plans; Interest Assumptions for Valuing Benefits
Starting January 31, 2026, new rules change how single-employer pension plans calculate the value of benefits when plans end. These updated interest assumptions affect plan sponsors and the Pension Benefit Guaranty Corporation, helping make sure money values match real market prices. If you’re involved with these plans, expect more accurate numbers for payouts and possible impacts on withdrawal costs.